title: Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
abstract: BACKGROUND
  Little is known about outcomes of acute myeloid leukemia (AML) in adolescents and young adults (AYA). The purpose of this study is to determine the characteristics and outcomes of AYA AML patients in comparison to older adult patients with AML.
  
  
  METHODS
  We retrospectively analyzed all AML patients treated at our institution from 1965 to 2009 who were aged 16 to 29 years.
  
  
  RESULTS
  Among 3922 adult AML patients treated during this period, 432 (11%) were identified as AYA. Median age was 23 years (range, 16-29 years); 73 (17%) patients had core binding factor (CBF)-AML [inversion (16), translocation (8:21)], and 51 (12%) had acute promyelocytic leukemia. Complete remission (CR) rates were 93% for CBF AML, 78% for APL, 77% with diploid karyotype, and 68% for other AML. Univariate analysis demonstrated higher rates of CR, CR duration, and overall survival (OS) in the AYA group compared with older patients. On multivariate analysis, AYA age group was independently associated with improved CR rate and CR duration, with a trend for longer OS (P = .085).
  
  
  CONCLUSIONS
  Outcome of AYA AML patients is overall better than for older adults with AML. Despite improvements in treatments and outcomes over time, there is still need for improvement in AYA with AML particularly for those with AML other than CBF and APL.
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Naveen
authors.initials: N
authors.lastname: Pemmaraju
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Farhad
authors.initials: F
authors.lastname: Ravandi
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Graciela M
authors.initials: GM
authors.lastname: Nogueras-Gonzalez
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Xuelin
authors.initials: X
authors.lastname: Huang
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Susan
authors.initials: S
authors.lastname: O'Brien
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: William
authors.initials: W
authors.lastname: Wierda
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Manero
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Deborah
authors.initials: D
authors.lastname: Thomas
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Sherry
authors.initials: S
authors.lastname: Pierce
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
authors.forename: Gautam
authors.initials: G
authors.lastname: Borthakur
authors.affiliation: Department of Leukemia, and Department of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX. Electronic address: jcortes@mdanderson.org.
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
keywords: Adherence; Diploid cytogenetics; FLT3 mutation; Older adult; Pediatric
references.citation: Leukemia. 2000 Apr;14(4):675-83
references.pmid: 10764154
references.citation: Am J Hematol. 2015 Jan;90(1):27-30
references.pmid: 25251041
references.citation: Leukemia. 2001 Aug;15(8):1256-61
references.pmid: 11480568
references.citation: Blood. 1999 May 1;93(9):3074-80
references.pmid: 10216104
references.citation: Blood. 2005 Dec 1;106(12):3740-6
references.pmid: 16051734
references.citation: Blood. 2006 May 1;107(9):3481-5
references.pmid: 16455952
references.citation: Oncologist. 2006 Jun;11(6):590-601
references.pmid: 16794238
references.citation: Cancer. 2006 Oct 1;107(7 Suppl):1645-55
references.pmid: 16906507
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1760-3
references.pmid: 17179473
references.citation: Blood. 2007 Aug 1;110(3):979-85
references.pmid: 17440048
references.citation: Cancer. 2007 Nov 1;110(9):1900-10
references.pmid: 17786921
references.citation: Haematologica. 2007 Nov;92(11):1519-32
references.pmid: 18024401
references.citation: Cancer. 2007 Dec 1;110(11):2385-93
references.pmid: 17918260
references.citation: Cancer. 2008 Feb 1;112(3):562-71
references.pmid: 18076087
references.citation: Nat Rev Cancer. 2008 Apr;8(4):288-98
references.pmid: 18354417
references.citation: Pediatr Blood Cancer. 2008 May;50(5 Suppl):1101-4
references.pmid: 18360838
references.citation: Blood. 2009 Feb 12;113(7):1408-11
references.pmid: 18974371
references.citation: Blood. 2009 Apr 16;113(16):3666-72
references.pmid: 19020306
references.citation: Semin Oncol. 2009 Jun;36(3):213-26
references.pmid: 19460579
references.citation: Cancer. 2009 Nov 1;115(21):4973-9
references.pmid: 19705347
references.citation: Ann Oncol. 2010 Feb;21(2):335-41
references.pmid: 19633049
references.citation: Hematol Oncol Clin North Am. 2010 Feb;24(1):35-63
references.pmid: 20113895
references.citation: Blood. 2010 Jul 22;116(3):354-65
references.pmid: 20385793
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4819-24
references.pmid: 20212259
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4800-9
references.pmid: 20212260
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4842-9
references.pmid: 20351337
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4790-9
references.pmid: 20439647
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4831-41
references.pmid: 20458029
references.citation: J Clin Oncol. 2010 Nov 10;28(32):4825-30
references.pmid: 20498401
references.citation: Hematology Am Soc Hematol Educ Program. 2010;2010:21-9
references.pmid: 21239766
references.citation: J Clin Oncol. 2011 Feb 10;29(5):487-94
references.pmid: 21220605
references.citation: Blood. 2011 Jun 2;117(22):5803-15
references.pmid: 21398581
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Br J Pharmacol. 2012 Jun;166(3):858-76
references.pmid: 22250956
references.citation: Haematologica. 2012 Jul;97(7):1029-35
references.pmid: 22271898
references.citation: Blood. 2012 Oct 18;120(16):3187-205
references.pmid: 22879540
references.citation: J Clin Oncol. 2012 Nov 10;30(32):4037-8; author reply 4038-9
references.pmid: 23032621
references.citation: CA Cancer J Clin. 2013 Jan;63(1):11-30
references.pmid: 23335087
references.citation: Br J Haematol. 2013 Jun;161(5):659-66
references.pmid: 23530930
references.citation: Curr Oncol Rep. 2013 Aug;15(4):317-24
references.pmid: 23757222
references.citation: Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):435-40
references.pmid: 23763915
references.citation: Qual Life Res. 2013 Aug;22(6):1339-51
references.pmid: 22922952
references.citation: Cancer. 2013 Dec 1;119(23):4162-9
references.pmid: 24104395
references.citation: Cancer. 2013 Dec 1;119(23):4170-9
references.pmid: 24104597
references.citation: CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
references.pmid: 24399786
references.citation: J Natl Compr Canc Netw. 2014 Jan;12(1):21-32; quiz 32
references.pmid: 24453290
references.citation: Expert Opin Investig Drugs. 2014 Jul;23(7):943-54
references.pmid: 24749672
references.citation: Acta Haematol. 2014;132(3-4):292-7
references.pmid: 25228554
references.citation: Acta Haematol. 2014;132(3-4):298-306
references.pmid: 25228555
references.citation: Br J Haematol. 2000 Oct;111(1):190-5
references.pmid: 11091200